Humanization and Characterization of an Anti-human TNF-α Murine Monoclonal Antibody

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Feb 10

PMID 21305012

Citations 16

Authors

Wei-Chun Chiu

Ya-Ping Lai

Min-Yuan Chou

Affiliations

Soon will be listed here.

Abstract

A murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-α) was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the framework regions of both the heavy and light chain variable regions were identified via a molecular modeling of m357 built by computer-assisted homology modeling. By replacing these critical surface residues with the human counterparts, a humanized version, h357, was generated. The humanized h357 IgG(1) was then stably expressed in a mammalian cell line and the purified antibody maintained the high antigen binding affinity as compared with the parental m357 based on a soluble TNF-α neutralization bioassay. Furthermore, h357 IgG(1) possesses the ability to mediate antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity upon binding to cells bearing the transmembrane form of TNF-α. In a mouse model of collagen antibody-induced arthritis, h357 IgG significantly inhibited disease progression by intra-peritoneal injection of 50 µg/mouse once-daily for 9 consecutive days. These results provided a basis for the development of h357 IgG as therapeutic use.

Citing Articles

Determination of functional similarity of biosimilar H9P2S from an investigational CHO clone with Adalimumab.

Gupta K, Desai R, Jawade K, Jagtap D, Modi D, Jain R 3 Biotech. 2022; 12(11):315.

PMID: 36276478 PMC: 9547763. DOI: 10.1007/s13205-022-03384-z.

The Use of Platelet-Rich Plasma for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review.

Han J, Gao F, Li Y, Ma J, Sun W, Shi L Biomed Res Int. 2020; 2020:2642439.

PMID: 32219128 PMC: 7081027. DOI: 10.1155/2020/2642439.

Adaption of human antibody λ and κ light chain architectures to CDR repertoires.

van der Kant R, Bauer J, Karow-Zwick A, Kube S, Garidel P, Blech M Protein Eng Des Sel. 2019; 32(3):109-127.

PMID: 31535139 PMC: 6908821. DOI: 10.1093/protein/gzz012.

Design and Construction of a Novel Humanized Single-Chain Variable-Fragment Antibody Against the Tumor Necrosis Factor Alpha.

Farajzadeh D, Karimi-Gharigh S, Jalali-Kondori P, Dastmalchi S Iran J Pharm Res. 2019; 18(1):308-319.

PMID: 31089365 PMC: 6487432.

Bone morphogenetic protein-2 exhibits therapeutic benefits for osteonecrosis of the femoral head through induction of cartilage and bone cells.

Wang C, Zang H, Zhou D Exp Ther Med. 2018; 15(5):4298-4308.

PMID: 29849774 PMC: 5962870. DOI: 10.3892/etm.2018.5941.

References

Verhoeyen M, Milstein C, Winter G . Reshaping human antibodies: grafting an antilysozyme activity. Science. 1988; 239(4847):1534-6. DOI: 10.1126/science.2451287. View

Staelens S, Desmet J, Ngo T, Vauterin S, Pareyn I, Barbeaux P . Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol. 2005; 43(8):1243-57. DOI: 10.1016/j.molimm.2005.07.018. View

Sandborn W, Feagan B, Stoinov S, Honiball P, Rutgeerts P, Mason D . Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357(3):228-38. DOI: 10.1056/NEJMoa067594. View

Scallon B, Moore M, Trinh H, Knight D, Ghrayeb J . Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995; 7(3):251-9. DOI: 10.1006/cyto.1995.0029. View

Feldmann M . Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5):364-71. DOI: 10.1038/nri802. View

Padlan E . A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol. 1991; 28(4-5):489-98. DOI: 10.1016/0161-5890(91)90163-e. View

Sandhu J . Protein engineering of antibodies. Crit Rev Biotechnol. 1992; 12(5-6):437-62. DOI: 10.3109/07388559209114235. View

Morrison S, Johnson M, Herzenberg L, Oi V . Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984; 81(21):6851-5. PMC: 392030. DOI: 10.1073/pnas.81.21.6851. View

Zhang W, Feng J, Li Y, Guo N, Shen B . Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol. 2005; 42(12):1445-51. DOI: 10.1016/j.molimm.2005.01.015. View

10.

Roguska M, Pedersen J, Keddy C, Henry A, Searle S, LAMBERT J . Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A. 1994; 91(3):969-73. PMC: 521435. DOI: 10.1073/pnas.91.3.969. View

11.

Schroff R, Foon K, Beatty S, Oldham R, Morgan Jr A . Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985; 45(2):879-85. View

12.

Queen C, SCHNEIDER W, Selick H, Payne P, Landolfi N, DUNCAN J . A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989; 86(24):10029-33. PMC: 298637. DOI: 10.1073/pnas.86.24.10029. View

13.

. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

14.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A . Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58(5):1248-57. DOI: 10.1002/art.23447. View

15.

Khachigian L . Collagen antibody-induced arthritis. Nat Protoc. 2007; 1(5):2512-6. DOI: 10.1038/nprot.2006.393. View

16.

Beenhouwer D, Wallis R, Broder M, Furst D . Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol. 2004; 31(10):1888-92. View

17.

Murali R, Helmer-Citterich M, Sharkey D, Scalice E, Daiss J, Sullivan M . Structural studies on an inhibitory antibody against Thermus aquaticus DNA polymerase suggest mode of inhibition. Protein Eng. 1998; 11(2):79-86. DOI: 10.1093/protein/11.2.79. View

18.

Aringer M, Smolen J . Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf. 2008; 7(4):411-9. DOI: 10.1517/14740338.7.4.411. View

19.

Arora T, Padaki R, Liu L, Hamburger A, Ellison A, Stevens S . Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009; 45(2):124-31. DOI: 10.1016/j.cyto.2008.11.008. View

20.

Owens R, Young R . The genetic engineering of monoclonal antibodies. J Immunol Methods. 1994; 168(2):149-65. DOI: 10.1016/0022-1759(94)90051-5. View